



## OPEN ACCESS

## EDITED BY

Florence Carrouel,  
Université Claude Bernard Lyon 1, France

## REVIEWED BY

Stepan Podzimek,  
Charles University, Czechia  
Flavia Vitiello,  
Marche Polytechnic University, Italy

## \*CORRESPONDENCE

Freja Frankenhaeuser,  
✉ freja.frankenhaeuser@helsinki.fi

## SPECIALTY SECTION

This article was submitted to  
Pharmacoepidemiology,  
a section of the journal  
Frontiers in Pharmacology

RECEIVED 17 January 2023

ACCEPTED 02 March 2023

PUBLISHED 13 March 2023

## CITATION

Frankenhaeuser F, Söder B, Källmén H,  
Korpi ER and Meurman JH (2023),  
Periodontitis may predict the use of  
prescription medicines later in life, a  
database study.  
*Front. Pharmacol.* 14:1146475.  
doi: 10.3389/fphar.2023.1146475

## COPYRIGHT

© 2023 Frankenhaeuser, Söder, Källmén,  
Korpi and Meurman. This is an open-  
access article distributed under the terms  
of the [Creative Commons Attribution  
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or  
reproduction in other forums is  
permitted, provided the original author(s)  
and the copyright owner(s) are credited  
and that the original publication in this  
journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Periodontitis may predict the use of prescription medicines later in life, a database study

Freja Frankenhaeuser<sup>1\*</sup>, Birgitta Söder<sup>2</sup>, Håkan Källmén<sup>3</sup>,  
Esa R. Korpi<sup>4</sup> and Jukka H. Meurman<sup>1</sup>

<sup>1</sup>Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, <sup>2</sup>Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden, <sup>3</sup>Stockholm Region Health Services, Stockholm, Sweden, <sup>4</sup>Department of Pharmacology, University of Helsinki, Helsinki, Finland

Medications used for the treatment of diseases also affect oral health. We investigated how having/not having periodontitis at baseline in 1985 was associated with purchases of medicines in the long term. The study paradigm is in the oral health-systemic health connections. We hypothesized that periodontitis links to purchases of medicines later in life. The study cohort consisted of 3,276 individuals from the greater Stockholm area, Sweden. Of them, 1,655 were clinically examined at baseline. Patients were followed-up for >35 years, using the national population and patient registers. The burden of systemic diseases and purchases of medicines were statistically analyzed comparing patients with ( $n = 285$ ) and without ( $n = 1,370$ ) periodontitis. The results showed that patients with periodontitis had purchased more of certain medications than non-periodontitis patients. Periodontitis patients purchased significantly more drugs used in diabetes ( $p = 0.035$ ), calcium channel blockers ( $p = 0.016$ ), drugs acting on the renin-angiotensin system ( $p = 0.024$ ), and nervous system drugs ( $p = 0.001$ ). Hence, patients with periodontitis indeed had purchased specific medications statistically significantly more than the periodontally healthy ones. This indicates that periodontitis, over time, might increase the risk for systemic diseases with the subsequent need for medication.

## KEYWORDS

periodontitis, medicines, systemic disease, oral health, prescription of drugs

## 1 Introduction

Periodontitis or periodontal disease is a chronic inflammation of the gums and tooth supporting tissues, leading to attachment and bone loss, due to the immune response caused by accumulations of bacterial biofilm on the teeth. Numerous studies have verified the link between poor oral health and systemic health (Meurman and Bascones-Martinez, 2021). In particular, periodontal disease is associated with cardiovascular diseases and diabetes, but also with many other diseases (Humphrey et al., 2008; Pussinen et al., 2022). Recently, periodontitis was shown to associate even with the outcome of COVID-19 (Marouf et al., 2021; Gupta et al., 2022). For example, in the study of Orilisi and coworkers (Orilisi et al., 2021) it was shown that patients with oral health problems were referred to intensive care more often than those without. The pathomechanism here involved is the chronic oral infection that upregulates many cytokines and inflammatory mediators with subsequent systemic organ effects (Hansen and Holmstrup, 2022).



**TABLE 1** Basic characteristics of the subjects. The table presents patients that have purchased medicines between the years 2005–2017. Data are given as n (%). Only *p*-values in line with our hypothesis are presented, due to our single sided hypothesis.

	Total (n = 1,665)	No-periodontitis (n = 1,370)	Periodontitis (n = 285)	<i>p</i> -value
Female	831	706 (85.0%)	125 (15.4%)	
Male	824	664 (80.6%)	160 (19.4%)	0.009
Non-smoker	618	907 (86.4%)	143 (13.6%)	
Smoker	605	463 (76.5%)	142 (23.5%)	<0.001
No earlier diagnosis	1,070	884 (82.6%)	186 (17.4%)	
Diagnosis in 1985	585	486 (83.1%)	99 (16.9%)	
Have not purchased medication	120	90 (75.0%)	30 (25.0%)	
Have purchased medication(s)	1,535	1,280 (83.4%)	255 (16.6%)	
Higher socio-economic status	1,315	1,097 (83.4%)	273 (16.6%)	
Lower socio-economic status	340	218 (80.3%)	67 (19.7%)	0.087

categorized in a dichotomized variable: a hospital diagnosis before 1985 was coded as one and no hospital diagnosis as 0, respectively. Hospitalization due to poisoning or pregnancy was disregarded.

## 2.6 Tobacco products

At baseline, the patient's use of tobacco products was registered. A dichotomized tobacco products variable was created where patients who were smoking or using Swedish snus in 1985 were coded as one and patients not using tobacco products were coded as 0.

## 2.7 Gender

Research has shown a difference in oral health among men and women, where men often have worse oral health. To take this into account a dichotomized variable was created where women were coded as 0 and men as 1.

## 2.8 Statistical analyses

Descriptive statistics, Chi<sup>2</sup>, *p*-tests, and logistic regression analyses were conducted in SPSS 28.0 software. A single-sided hypothesis was used in this study, resulting in the use of one-tailed tests. Descriptive statistics as frequencies were conducted, differences between groups were tested by Mann-Whitney *U*-tests, and differences in the distribution of data were analyzed by Chi<sup>2</sup>. Logistic regression analyses of procurement of medicines with periodontitis as explaining variable were controlled for gender (men 1, women 0), tobacco products (yes 1, no 0), socio-economic (lower 1, higher 0), and if the subject had a diagnosis of systemic disease before 1985 (yes 1, no 0). Data reorganization and summation of the different registers were made in Visual Studio Code 2, Python 3.9.10 64-bit.

## 3 Results

The number of patients with periodontitis, tobacco usage, gender, and diagnoses at baseline are given in Table 1. Patients with periodontitis had not purchased more medications than the non-periodontitis subjects between the years 2005–2017. Fewer patients with periodontitis had acquired medications in general than periodontally healthy individuals (89.5% vs 93.4%). The medication categories most patients had purchased during the timespan was ATC category J, anti-infectives for systemic use (n = 1,379), as can be seen in Table 2. The second in frequency was medicines used for diseases of the nervous system (n = 1,197) and, third, respiratory medications (n = 1,157). Comparing the purchases by periodontitis patients with those of the periodontally healthy, periodontitis patients had purchased more drugs of the ATC category C, cardiovascular system, L, antineoplastic and immunomodulating agents, and P, antiparasitic products, insecticides and repellents (Table 2).

Looking at the pharmaceutical groups of drugs according to the ATC classification, there were medicines in five different groups that had been purchased more by the periodontally diseased patients. These were drugs used for diabetes (*p* = 0.035), calcium channel blockers (*p* = 0.016), drugs acting on the renin-angiotensin system (*p* = 0.032), lipid modifying agents (*p* = 0.024), and drugs used for other nervous system diseases (*p* = 0.001). Another fourteen different categories of medications used more by the periodontitis patients (*p* = 0.102–0.462) were cardiovascular drugs and beta-blocking agents, in particular, antineoplastic agents, drugs for endocrine diseases, immunosuppressants, anti-inflammatory, and antirheumatic drugs, topical products for joint and muscular pain, muscle relaxants, antigout preparations, analgesics, antiepileptics, antiparkinson drugs, psycholeptics (antipsychotics, anxiolytics, hypnotics, and sedatives) and antiprotozoals. The details are given in Table 3.

When looking at the ATC subclasses and specific drug preparations, differences were also detected in the purchase numbers of medicines between the periodontitis and non-periodontitis groups. In addition to the results given in Table 3,

**TABLE 2 Distributions of different medication groups purchased in the ATC categories. Only *p*-values in line with our hypothesis are presented, due to our single sided hypothesis.**

Alimentary tract and metabolism	Total	No periodontitis	Periodontitis	<i>p</i> -value
Have not purchased	540	441 (81.7%)	99 (18.3%)	
Have purchased	1,115	929 (83.3%)	186 (16.7%)	
<b>Blood and blood forming organs</b>				
Have not purchased	889	739 (83.1%)	150 (16.9%)	
Have purchased	766	631 (82.4%)	135 (17.6%)	0.344
<b>Cardiovascular system</b>				
Have not purchased	640	539 (84.2%)	101 (15.8%)	
Have purchased	1,015	831 (81.9%)	184 (18.1%)	0.109
<b>Dermatologicals</b>				
Have not purchased	683	566 (82.9%)	127 (18.6%)	
Have purchased	962	804 (83.6%)	158 (16.4%)	
<b>Genito-urinary system and sex hormones</b>				
Have not purchased	835	689 (82.5%)	146 (17.5%)	
Have purchased	820	681 (83.0%)	139 (17.0%)	
<b>Systemic hormonal preparations, excluding sex hormones and insulins</b>				
Have not purchased	1,078	878 (81.4%)	200 (18.6%)	
Have purchased	557	492 (88.3%)	85 (15.3%)	
<b>Anti-infectives for systemic use</b>				
Have not purchased	276	228 (82.6%)	48 (17.4%)	
Have purchased	1,379	1,142 (82.8%)	237 (17.2%)	
<b>Antineoplastic and immunomodulating agents</b>				
Have not purchased	1,481	1,231 (83.1%)	250 (16.9%)	
Have purchased	174	139 (79.9%)	35 (20.1%)	0.143
<b>Musculo-skeletal system</b>				
Have not purchased	502	415 (82.7%)	87 (17.3%)	
Have purchased	1,153	955 (82.8%)	198 (17.2%)	
<b>Nervous system</b>				
Have not purchased	458	377 (82.3%)	81 (17.7%)	
Have purchased	1,197	993 (83.0%)	204 (17.0%)	
<b>Antiparasitic products, insecticides and repellents</b>				
Have not purchased	1,301	1,084 (83.3%)	217 (16.7%)	
Have purchased	354	286 (80.8%)	68 (19.2%)	0.132
<b>Respiratory system</b>				
Have not purchased	498	404 (81.1%)	94 (18.9%)	
Have purchased	1,157	966 (83.5%)	191 (16.5%)	
<b>Sensory organs</b>				
Have not purchased	813	668 (82.2%)	145 (17.8%)	
Have purchased	842	702 (83.4%)	140 (16.6%)	
<b>Various</b>				
Have not purchased	1,633	1,350 (82.7%)	283 (17.3%)	
Have purchased	22	20 (90.9%)	2 (9.1%)	

**TABLE 3 Drugs most frequently purchased within the ATC categories. The statistically significant distribution in favor of periodontitis patients are bolded.**

ATC classification	Total	Non-periodontitis		Periodontitis		p-value
<b>Alimentary tract and metabolism</b>						
<b>Drugs used in diabetes</b>						
Have not purchased	1,499	1,249	(83.3%)	250	(16.7%)	
Have purchased	156	121	(77.6%)	35	(22.4%)	0.035
<b>Cardiovascular system</b>						
<b>Cardiac therapy</b>						
Have not purchased	1,444	1,198	(83.0%)	246	(17.0%)	
Have purchased	211	172	(81.5%)	39	(18.5%)	0.300
<b>Beta blocking agents</b>						
Have not purchased	1,178	982	(83.4%)	196	(16.6%)	
Have purchased	477	388	(81.3%)	89	(18.7%)	0.162
<b>Calcium channel blockers</b>						
Have not purchased	1,271	1,066	(83.9%)	205	(16.1%)	
Have purchased	384	304	(79.2%)	80	(20.8%)	0.016
<b>Agents acting on the renin-angiotensin system</b>						
Have not purchased	1,055	887	(84.1%)	168	(15.9%)	
Have purchased	600	483	(80.5%)	117	(19.5%)	0.032
<b>Lipid modifying agents</b>						
Have not purchased	1,139	957	(84.0%)	182	(16.0%)	
Have purchased	519	182	(35.1%)	103	(19.8%)	0.024
<b>Antineoplastic and immunomodulating agents</b>						
<b>Antineoplastic agents</b>						
Have not purchased	1,601	1,328	(82.9%)	273	(17.1%)	
Have purchased	54	42	(77.8%)	12	(22.2%)	0.161
<b>Endocrine therapy</b>						
Have not purchased	1,588	1,315	(82.8%)	273	(17.2%)	
Have purchased	67	55	(82.1%)	12	(17.9%)	0.440
<b>Immunosuppressants</b>						
Have not purchased	1,601	1,326	(82.8%)	275	(17.2%)	
Have purchased	54	44	(81.5%)	10	(18.5%)	0.399
<b>Musculo-skeletal system</b>						
<b>Anti-inflammatory and antirheumatic products</b>						
Have not purchased	561	467	(83.2%)	98	(17.5%)	
Have purchased	1,094	903	(82.5%)	191	(17.5%)	0.360
<b>Topical products for joint and muscular pain</b>						
Have not purchased	1,484	1,230	(82.9%)	254	(17.1%)	
Have purchased	171	140	(81.9%)	31	(18.1%)	0.370
<b>Muscle relaxants</b>						
Have not purchased	1,484	1,231	(83.0%)	253	(17.0%)	
Have purchased	171	139	(81.3%)	32	(18.7%)	0.293
<b>Antigout preparations</b>						

(Continued on following page)

**TABLE 3 (Continued) Drugs most frequently purchased within the ATC categories. The statistically significant distribution in favor of periodontitis patients are bolded.**

ATC classification	Total	Non-periodontitis		Periodontitis		p-value
Have not purchased	1,587	1,316	(82.9%)	271	(17.1%)	
Have purchased	68	54	(79.4%)	14	(20.6%)	0.227
<b>Nervous system</b>						
<b>Analgesics</b>						
Have not purchased	643	538	(83.7%)	105	(16.3%)	
Have purchased	1,012	832	(82.2%)	180	(17.8%)	0.222
<b>Antiepileptics</b>						
Have not purchased	1,526	1,268	(83.1%)	258	(16.9%)	
Have purchased	129	102	(79.1%)	27	(20.9%)	0.123
<b>Anti-parkinson drugs</b>						
Have not purchased	1,607	1,331	(82.8%)	276	(17.2%)	
Have purchased	48	39	(81.3%)	9	(18.8%)	0.388
<b>Psycholeptics</b>						
Have not purchased	974	807	(82.9%)	167	(17.1%)	
Have purchased	681	563	(82.7%)	118	(17.3%)	0.462
<b>Other nervous system drugs</b>						
Have not purchased	1,548	1,293	(83.5%)	255	(16.5%)	
Have purchased	107	77	(72.0%)	30	(28.0%)	0.001
<b>Antiparasitic products, insecticides and repellents</b>						
<b>Antiprotozoals</b>						
Have not purchased	1,312	1,094	(83.4%)	218	(16.6%)	
Have purchased	343	276	(80.5%)	67	(19.5%)	0.102

purchases of 18 specific drug preparations were significantly more common among periodontitis patients. They purchased more of the following preparations: insulin (2.46% vs. 0.95%,  $p = 0.017$ ), calcium channel blocker felodipine (8.42% vs. 5.62%,  $p = 0.036$ ), angiotensin-converting enzyme (ACE) inhibitor ramipril (4.91% vs. 2.99%,  $p = 0.05$ ), HMG CoA reductase inhibitor simvastatin (29.4% vs. 22.6%,  $p = 0.007$ ), opioid analgesics ketobemidone (3.16% vs. 1.09%,  $p = 0.004$ ) and fentanyl (1.75% vs. 0.58%,  $p = 0.021$ ), nicotine dependence drug varenicline (5.26%–2.04%,  $p = 0.001$ ), and the nitroimidazole antibiotic metronidazole (17.5% vs. 12.4%,  $p = 0.01$ ). Eleven preparations were excluded from the list because less than five subjects had purchased them.

In total, 77 different individual preparations had been purchased more often by the periodontitis patients than the periodontally healthy. Among the 59 preparations that had not been significantly more purchased there were 17 different individual diabetes medications ( $p = 0.017$ – $0.323$ ), the channel blocker amlodipine (22.5% vs 18.8%,  $p = 0.076$ ), ACE-inhibitor enalapril (25.6% vs 21.3%,  $p = 0.056$ ), disulfiram (1.4% vs 0.7%,  $p = 0.097$ ), analgesic morphine, and antispasmodics (2.5%–1.5%,  $p = 0.114$ ).

Odds ratios for the different categories of medications mainly linked to periodontitis are given in Table 4 and Table 5. In the main

categories and subtypes of medications purchased, positive odds ratios, with a confidence interval over one, were not detected. Regarding individual preparations, only simvastatin (ATC class C10AA01, OR = 1.4; CI = 1.04–1.86), ketobemidone (ATC class N02AB01, OR = 3.32; CI = 1.48–7.86) and metronidazole (ATC class P01AB01, OR = 1.46; CI = 1.03–2.08) showed positive odds ratios.

## 4 Discussion

To our knowledge, this is the first study investigating the procurement of medications and specific drug preparations in a 35-year perspective since the diagnosis of periodontitis, compared to the periodontally healthy subjects at baseline. The main finding was that periodontitis patients had purchased certain, but not at all medications, more frequently than we had expected. Hence, the patients did not tend to buy more medications in general, and differences were only seen between the periodontitis and periodontally healthy groups when analyzing the various ATC categories of medicines and the specific preparations within the categories. The results thus only partly confirmed our study hypothesis.

**TABLE 4** Linear regressions and odds ratios (OR) with confidence intervals (CI) of drug categories associated with having periodontitis in 1985.

Cofactors		OR	95% CI for OR	
Nervous system			Lower	Upper
	Periodontitis	0.957	0.714	1.28
	Male	0.553	0.442	0.692
	Smoker	1.49	1.17	1.89
	Prior diagnosis to 1985	1.54	1.21	1.96
	Lower socioeconomic	0.634	0.487	0.825
Alimentary tract and metabolism				
	Periodontitis	0.932	0.707	1.22
	Male	0.612	0.495	0.756
	Smoker	1.06	0.850	1.32
	Prior diagnosis to 1985	1.61	1.28	2.02
	Lower socioeconomic	0.653	0.507	0.840
Cardiovascular system				
	Periodontitis	1.16	0.888	1.52
	Male	0.989	0.808	1.20
	Smoker	1.19	0.969	1.47
	Prior diagnosis to 1985	1.44	1.16	1.78
	Lower socioeconomic	0.796	0.622	1.01
Antineoplastic and immunomodulating agents				
	Periodontitis	1.27	0.852	1.90
	Male	0.633	0.457	0.877
	Smoker	1.12	0.809	1.55
	Prior diagnosis to 1985	1.25	0.903	1.73
	Lower socioeconomic	0.814	0.538	1.22

This area of research has been scarcely investigated earlier. Only one prior article was found on the use of systemic medications by periodontitis patients (Wang et al., 2020). Compared to that, our study showed fewer significant results. But it should be pointed out that the study by Wang and collaborators investigated matched subjects while our study was a longitudinal cohort study.

Nevertheless, results similar to those of the study of Wang et al. were found for insulin, oral hypoglycemics in general, ACE inhibitors, calcium channel blockers, lipid-lowering medications, and alpha-2 agonists. However, contrary to Wang et al., we could not establish a connection between periodontitis patients and the use of diuretics, anti-coagulants, bronchodilators, antidepressants, antipsychotic drugs, and anticonvulsants. This indeed can be explained by the differences in the study design and subjects.

As said, hundreds of different systemic medications affect the oral cavity. The main effect is hyposalivation with consequent

**TABLE 5** Linear regressions and odds ratios (OR) with confidence intervals (CI) of individual medications associated with having periodontitis in 1985.

Cofactors		OR	95% CI for OR	
Simvastatin				
	Periodontitis	1.39	1.04	1.86
	Male	1.14	0.909	1.44
	Smoker	1.15	0.914	1.46
	Systemic diagnosis in 1985	1.16	0.916	1.47
	Low socioeconomic status	0.790	0.589	1.05
Ketobemidone				
	Periodontitis	3.32	1.40	7.86
	Male	0.541	0.226	1.29
	Smoker	0.631	0.260	1.53
	Systemic diagnosis in 1985	3.48	1.46	8.32
	Low socioeconomic status	1.53	0.619	3.80
Metronidazole				
	Periodontitis	1.46	1.03	2.08
	Male	0.567	0.422	0.762
	Smoker	1.51	1.13	2.03
	Systemic diagnosis in 1985	0.818	0.602	1.11
	Low socioeconomic status	1.01	0.712	1.44

xerostomia (Tanasiewicz et al., 2016). The salivation-altering medications identified in the present study were angiotensin II receptor blockers, analgesics, anti-infectives, anti-inflammatory medications, alpha-2 agonists, antigout medications, cardiovascular medications like calcium channel blockers, drugs used for diabetes, and those for nicotine dependence, immunosuppressants, and interferons and statins, respectively (Pająk-Lysek et al., 2021; Choo et al., 2022). Hyposalivation is a serious issue because it can increase the risk of diseases of the oral cavity. Poor oral health is also linked to a decrease in the patient's quality of life (Barbe, 2018).

Xerostomia has been shown to affect 34%–51% of diabetic patients mainly through salivary dysfunction. The linkage between periodontitis and diabetes is well understood because poor glycemic control does worsen periodontal health (Rohani, 2019). Hence, it was no surprise that metformin and the 12 other diabetic medications here encountered were purchased more often by patients with periodontitis.

Merely three systemic individual preparations, namely simvastatin, ketobemidone, and metronidazole showed a positive odds ratio for long-term periodontitis in the present study. No research has been made on a link between opioids or painkillers and periodontitis diagnosis. Similar to our findings, a recent study, however, showed a connection between statins and periodontitis (Kwon et al., 2022). The use of antibiotics as a part of periodontal care varies substantially, necessitating clear guidelines (Feres et al., 2015). In Sweden, antibiotics are rarely

used in standard periodontal care. Purchasing metronidazole more often, an antibiotic used mainly for Gram-positive bacteria and protozoa, would thereby indicate that either periodontal disease would increase the risk of infections or infections increase the risk of developing periodontitis. This, however, could not be verified based on the present material.

To account for the impact of long-term systemic medication before 1985 at the onset of this study, patients diagnosed with systemic diseases were identified by using the Swedish national registers for hospital treatment and open care. This was taken into account in the logistic regression analyses and having at least one diagnosis before 1985 was found to significantly increase the risk of purchasing the majority of ATC categories analyzed. Exceptions in this regard were drugs for diseases of the genito-urinary system, sex hormones, anti-infectives for systemic use, drugs for skin diseases, antiparasitic preparations, insecticides and repellents, and, finally, antineoplastic and immunomodulating agents.

A significant difference in the specific medication purchases was seen only in a few drug preparations in this study. This is not in line with current research on the connection between periodontitis and systemic diseases (Liccardo et al., 2019). When compared with patients without periodontitis, there was no significant difference in the purchase of cancer medications, and anti-rheumatic and neurological medication. This finding was unexpected as both different subtypes of cancers, rheumatic and neurological diseases such as Alzheimer's and depression have been linked to periodontitis (Michaud et al., 2017; Nwizu et al., 2020; Kavarthapu and Gurumoorthy, 2021; Tuominen and Rautava, 2021; Zheng et al., 2021; Asher et al., 2022). Furthermore, the finding is not in line with our earlier research (Söder et al., 2015). However, the present results only represent the sample here used and do not necessarily give the full picture of the whole cohort.

Several covariables have been taken into account in this research. For instance, the purchasing of varenicline, a nicotine-dependence drug, is closely linked with tobacco use. Since a large percentage of the periodontitis patients were smokers, their purchasing varenicline could be expected. Smoking is a well-known risk factor affecting both systemic and periodontal health (Leite et al., 2018). Gender is another important factor as there are differences in oral health between men and women and likewise so when considering socioeconomic status (Boillot et al., 2011; Leng et al., 2015). Interestingly, our odds ratios showed only a few positive results regarding lower socio-economic status and gender, and only partly so concerning tobacco usage.

The strength of the present study is that it offers unique and substantial material with a long follow-up period. The multitude of preparations and a large number of purchases thus made the investigation reliable. This, as well as the relatively big sample size, allowed for conducting the detailed analysis. However, there is room for improvement when planning further studies. The size of the cohort could still be increased if possible. For example, melphalan, vinorelbine, pizotifen, betahistine, and riluzole were only used by one patient in the present material. Thus, there was no way to draw further conclusions in that respect. Furthermore, since the beginning of the study, the diagnostic criteria for

periodontitis have been changed several times. Hence, if the most recent diagnostic criteria would have been used the material might look different. This is another weakness of the present study. Nevertheless, we have found a link between medication purchases and periodontitis, especially when looking at the specific preparations and subgroups of medications. Finally, this area has been sparsely studied before and, subsequently, studies with other cohorts are needed.

## 5 Conclusion

We conclude that patients with periodontitis had purchased only a few medication groups more than periodontally healthy subjects when looking at the main drug categories. This finding was contrary to our expectations. On the other hand, periodontitis patients had purchased more than 19 different subgroups of medications. These included diabetes drugs, calcium channel blockers, agents acting on the renin-angiotensin system, statins, and drugs for diseases of the nervous system. Of the specific preparations, only simvastatin, ketobemidone, and metronidazole had been purchased significantly more often by the periodontitis patients. Many of these drugs cause hyposalivation as their side effect which must be taken into account when counseling patients in general.

## Data availability statement

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

## Ethics statement

The studies involving human participants were reviewed and approved by The Ethics Committee of the Karolinska University Hospital at Huddinge (Dnr 2007/1669-31; 2012/590-32; 2017/2204-32). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

## Author contributions

BS, JM, EK, and HK: conceptualization of overarching research goals and aims. FF and HK: data/evidence collection and formal analysis of the data. All authors participated in writing the manuscript and its critical review and revision.

## Funding

The study was supported by Ministry of Health and Social Affairs (grants F84/189), the Karolinska Institutet, Sweden, and grants from The Finnish Society of Sciences and Letters, the Finnish Medical Society, Finland, and King Gustav V's and Queen Victoria Freemason's Foundation, Sweden.



## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2023.1146475/full#supplementary-material>

## References

- Asher, S., Stephen, R., Mäntylä, P., Suominen, A. L., and Solomon, A. (2022). Periodontal health, cognitive decline, and dementia: A systematic review and meta-analysis of longitudinal studies. *J. Am. Geriatr. Soc.* 70, 2695–2709. doi:10.1111/jgs.17978
- Barbe, A. G. (2018). Medication-Induced xerostomia and hyposalivation in the elderly: Culprits, complications, and management. *Drugs Aging* 35, 877–885. doi:10.1007/s40266-018-0588-5
- Boillot, A., El Halabi, B., Batty, G. D., Rangé, H., Czernichow, S., and Bouchard, P. (2011). Education as a predictor of chronic periodontitis: A systematic review with meta-analysis population-based studies. *PLoS One* 6, e21508. doi:10.1371/journal.pone.0021508
- Choo, P. J., Taing, M. W., and Teoh, L. (2022). A retrospective study of drugs associated with xerostomia from the Australian Database of Adverse Event Notifications. *Int. J. Pharm. Pract.* 30, 548–553. doi:10.1093/ijpp/riac051
- Feres, M., Figueiredo, L. C., Soares, G. M., and Faveri, M. (2015). Systemic antibiotics in the treatment of periodontitis. *Periodontol.* 2000, 67, 131–186. doi:10.1111/prd.12075
- Glick, A., Sista, V., and Johnson, C. (2020). Oral manifestations of commonly prescribed drugs. *Am. Fam. Physician* 102, 613–621.
- Gupta, S., Saarikko, M., Pfützner, A., Räisänen, I. T., and Sorsa, T. (2022). Compromised periodontal status could increase mortality for patients with COVID-19. *Lancet Infect. Dis.* 22, 314. doi:10.1016/S1473-3099(22)00065-2
- Hansen, P. R., and Holmstrup, P. (2022). Cardiovascular diseases and periodontitis. *Adv. Exp. Med. Biol.* 1373, 261–280. doi:10.1007/978-3-030-96881-6\_14
- Humphrey, L. L., Fu, R., Buckley, D. I., Freeman, M., and Helfand, M. (2008). Periodontal disease and coronary heart disease incidence: A systematic review and meta-analysis. *J. Gen. Intern. Med.* 23, 2079–2086. doi:10.1007/s11606-008-0787-6
- Kaur, G., Verhamme, K. M., Dieleman, J. P., Vanrolleghem, A., Van Soest, E. M., Stricker, B. H., et al. (2010). Association between calcium channel blockers and gingival hyperplasia. *J. Clin. Periodontol.* 37, 625–630. doi:10.1111/j.1600-051X.2010.01574.x
- Kavarthapu, A., and Gurumoorthy, K. (2021). Linking chronic periodontitis and oral cancer: A review. *Oral Oncol.* 121, 105375. doi:10.1016/j.oraloncology.2021.105375
- Kwon, M. J., Byun, S. H., Kim, J. H., Kim, J. H., Kim, S. H., Kim, N. Y., et al. (2022). Longitudinal follow-up study of the association between statin use and chronic periodontitis using national health screening cohort of Korean population. *Sci. Rep.* 12, 5504. doi:10.1038/s41598-022-09540-y
- Leite, F. R. M., Nascimento, G. G., Scheutz, F., and López, R. (2018). Effect of smoking on periodontitis: A systematic review and meta-regression. *Am. J. Prev. Med.* 54, 831–841. doi:10.1016/j.amepre.2018.02.014
- Leng, B., Jin, Y., Li, G., Chen, L., and Jin, N. (2015). Socioeconomic status and hypertension: A meta-analysis. *J. Hypertens.* 33, 221–229. doi:10.1097/HJH.0000000000000428
- Liccardo, D., Cannavo, A., Spagnuolo, G., Ferrara, N., Cittadini, A., Rengo, C., et al. (2019). Periodontal disease: A risk factor for diabetes and cardiovascular disease. *Int. J. Mol. Sci.* 20, 1414. doi:10.3390/ijms20061414
- Marouf, N., Cai, W., Said, K. N., Daas, H., Diab, H., Chinta, V. R., et al. (2021). Association between periodontitis and severity of COVID-19 infection: A case-control study. *J. Clin. Periodontol.* 48, 483–491. doi:10.1111/jcpe.13435
- Meurman, J. H., and Bascones-Martinez, A. (2021). Oral infections and systemic health - more than just links to cardiovascular diseases. *Oral Health Prev. Dent.* 19, 441–448. doi:10.3290/j.ohpd.b1993965
- Michaud, D. S., Fu, Z., Shi, J., and Chung, M. (2017). Periodontal disease, tooth loss, and cancer risk. *Epidemiol. Rev.* 39, 49–58. doi:10.1093/epirev/mxx006
- Miranda-Rius, J., Brunet-Llobet, L., Lahor-Soler, E., and Farré, M. (2015). Salivary secretory disorders, inducing drugs, and clinical management. *Int. J. Med. Sci.* 12, 811–824. doi:10.7150/ijms.12912
- Mizutani, S., Ekuni, D., Tomofuji, T., Azuma, T., Kataoka, K., Yamane, M., et al. (2015). Relationship between xerostomia and gingival condition in young adults. *J. Periodontol. Res.* 50, 74–79. doi:10.1111/jre.12183
- Närhi, T. O., Meurman, J. H., Ainamo, A., Nevalainen, J. M., Schmidt-Kaunisaho, K. G., Siukosaari, P., et al. (1992). Association between salivary flow rate and the use of systemic medication among 76-81- and 86-year-old inhabitants in Helsinki, Finland. *J. Dent. Res.* 71, 1875–1880. doi:10.1177/00220345920710120401
- Nwizu, N., Wactawski-Wende, J., and Genco, R. J. (2020). Periodontal disease and cancer: Epidemiologic studies and possible mechanisms. *Periodontol.* 2000, 83, 213–233. doi:10.1111/prd.12329
- Orlisci, G., Mascitti, M., Togni, L., Monterubbianesi, R., Tosco, V., Vitiello, F., et al. (2021). Oral manifestations of COVID-19 in hospitalized patients: A systematic review. *Int. J. Environ. Res. Public Health* 18, 12511. doi:10.3390/ijerph182312511
- Pajak-Lysek, E., Polak, M., Kopeć, G., Podolec, M., Desvarieux, M., Pajak, A., et al. (2021). Associations between pharmacotherapy for cardiovascular diseases and periodontitis. *Int. J. Environ. Res. Public Health* 18, 770. doi:10.3390/ijerph18020770
- Pussinen, P. J., Kopra, E., Pietiäinen, M., Lehto, M., Zarić, S., Paju, S., et al. (2022). Periodontitis and cardiometabolic disorders: The role of lipopolysaccharide and endotoxemia. *Periodontol.* 2000, 89, 19–40. doi:10.1111/prd.12433
- Rees, T. D. (1998). Drugs and oral disorders. *Periodontol.* 2000, 18, 21–36. doi:10.1111/j.1600-0757.1998.tb00136.x
- Rohani, B. (2019). Oral manifestations in patients with diabetes mellitus. *World J. Diabetes* 10, 485–489. doi:10.4239/wjcd.v10.i9.485
- Söder, B., Andersson, L. C., Meurman, J. H., and Söder, P. (2015). Unique database study linking gingival inflammation and smoking in carcinogenesis. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 370, 20140041. doi:10.1098/rstb.2014.0041
- Söder, P. O., Jin, L. J., Söder, B., and Wikner, S. (1994). Periodontal status in an urban adult population in Sweden. *Community Dent. Oral Epidemiol.* 22, 106–111. doi:10.1111/j.1600-0528.1994.tb01582.x
- Tanasiewicz, M., Hildebrandt, T., and Obersztyn, I. (2016). Xerostomia of various etiologies: A review of the literature. *Adv. Clin. Exp. Med.* 25, 199–206. doi:10.17219/acem/29375
- Trackman, P. C., and Kantarci, A. (2015). Molecular and clinical aspects of drug-induced gingival overgrowth. *J. Dent. Res.* 94, 540–546. doi:10.1177/0022034515571265
- Tuominen, H., and Rautava, J. (2021). Oral microbiota and cancer development. *Pathobiology* 88, 116–126. doi:10.1159/000510979
- Wang, I. C., Askar, H., Ghassib, I., Wang, C. W., and Wang, H. L. (2020). Association between periodontitis and systemic medication intake: A case-control study. *J. Periodontol.* 91, 1245–1255. doi:10.1002/JPER.19-0593
- Yuan, A., and Woo, S. B. (2020). Adverse drug events in the oral cavity. *Dermatol Clin.* 38, 523–533. doi:10.1016/j.det.2020.05.012
- Zheng, D. X., Kang, X. N., Wang, Y. X., Huang, Y. N., Pang, C. F., Chen, Y. X., et al. (2021). Periodontal disease and emotional disorders: A meta-analysis. *J. Clin. Periodontol.* 48, 180–204. doi:10.1111/jcpe.13395